Phase 3
Completed N=196
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Source: ClinicalTrials.gov NCT03196791 ↗Enrolled (actual)
196
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcomePrimary: Number of Retrieved Lymph Nodes Per Participant — 44.6; 41.5; 49.2; 39.2 lymph nodes
◆ Published Evidence
Emerging
8citations · ~2 / year
Impact of the Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients: A Randomized Clinical Trial.
Summary
This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25. The primary endpoint is number of harvested lymph node that is critical point regarding quality of surgery in gastric cancer treatment. The secondary endpoint is intraoperative bleeding, surgeons' satisfaction.
The patients were randomly assigned to two groups using a computer-generated randomization table : 196 persons
* Deep neuromuscular block group (98persons)
* Moderate neuromuscular group (98persons)
Linked Publications (2)
-
Impact of the Deep Neuromuscular Block on Oncologic Quality of Laparoscopic Surgery in Obese Gastric Cancer Patients: A Randomized Clinical Trial.
-
Comparison of oncological benefits of deep neuromuscular block in obese patients with gastric cancer (DEBLOQS_GC study): A study protocol for a double-blind, randomized controlled trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Retrieved Lymph Nodes Per Participant |
44.6; 41.5; 49.2; 39.2 | — |
| SECONDARY Surgical Rating Score (SRS) |
4.4; 4.3; 4.2; 4.1; 4.2; 4.2 | — |
| SECONDARY Number of Participants With at Least One Interruption Event |
19; 34 | — |
| SECONDARY Intraoperative Blood Loss Amount |
77.5; 74.2 | — |
Eligibility Criteria
Inclusion Criteria
- Gastric cancer patients with laparoscopic subtotal gastrectomy
- 19-75 years
- Body mass index(BMI) > 25kg/m2
- American Society of Anesthesiologists I-III
Exclusion Criteria
- American Society of Anesthesiologists Class IV
- End stage renal disease (ESRD) patient
- Patients with allergy to muscle relaxants
- Patients with diseases that may affect muscle relaxation
Data sourced from ClinicalTrials.gov (NCT03196791) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.